Imodium Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy
Condition:   HER2-positive Breast Cancer Interventions:   Drug: Neratinib;   Drug: Trastuzumab;   Drug: Crofelemer;   Drug: Loperamide Sponsors:   University of California, San Francisco;   Puma Biotechnology, Inc.;   Napo Pharmaceuticals, Inc. Recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 14, 2017 Category: Research Source Type: clinical trials